Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report
A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of...
Ausführliche Beschreibung
Autor*in: |
---|
Format: |
E-Artikel |
---|
Erschienen: |
De Gruyter ; 2013 |
---|
Schlagwörter: |
---|
Umfang: |
4 |
---|
Reproduktion: |
Walter de Gruyter Online Zeitschriften |
---|---|
Übergeordnetes Werk: |
Enthalten in: The journal of pediatric endocrinology and metabolism - Berlin [u.a.] : de Gruyter, 1985, 26(2013), 7-8 vom: 02. Apr., Seite 785-788 |
Übergeordnetes Werk: |
volume:26 ; year:2013 ; number:7-8 ; day:02 ; month:04 ; pages:785-788 ; extent:4 |
Links: |
---|
DOI / URN: |
10.1515/jpem-2013-0064 |
---|
Katalog-ID: |
NLEJ247123161 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLEJ247123161 | ||
003 | DE-627 | ||
005 | 20220820030443.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220814s2013 xx |||||o 00| ||und c | ||
024 | 7 | |a 10.1515/jpem-2013-0064 |2 doi | |
028 | 5 | 2 | |a artikel_Grundlieferung.pp |
035 | |a (DE-627)NLEJ247123161 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
245 | 1 | 0 | |a Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report |
264 | 1 | |b De Gruyter |c 2013 | |
300 | |a 4 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. | ||
533 | |f Walter de Gruyter Online Zeitschriften | ||
650 | 4 | |a anti-GH antibodies | |
650 | 4 | |a growth hormone (GH) deficiency | |
650 | 4 | |a growth hormone (GH) therapy | |
700 | 1 | |a Meazza, Cristina |4 oth | |
700 | 1 | |a Schaab, Michael |4 oth | |
700 | 1 | |a Pagani, Sara |4 oth | |
700 | 1 | |a Calcaterra, Valeria |4 oth | |
700 | 1 | |a Bozzola, Elena |4 oth | |
700 | 1 | |a Kratzsch, Juergen |4 oth | |
700 | 1 | |a Bozzola, Mauro |4 oth | |
773 | 0 | 8 | |i Enthalten in |t The journal of pediatric endocrinology and metabolism |d Berlin [u.a.] : de Gruyter, 1985 |g 26(2013), 7-8 vom: 02. Apr., Seite 785-788 |w (DE-627)NLEJ248236202 |w (DE-600)2583847-7 |x 2191-0251 |7 nnns |
773 | 1 | 8 | |g volume:26 |g year:2013 |g number:7-8 |g day:02 |g month:04 |g pages:785-788 |g extent:4 |
856 | 4 | 0 | |u https://doi.org/10.1515/jpem-2013-0064 |z Deutschlandweit zugänglich |
912 | |a GBV_USEFLAG_U | ||
912 | |a ZDB-1-DGR | ||
912 | |a GBV_NL_ARTICLE | ||
951 | |a AR | ||
952 | |d 26 |j 2013 |e 7-8 |b 02 |c 04 |h 785-788 |g 4 |
matchkey_str |
article:21910251:2013----::eeomnoatbdeaantrwhomngdrnrgteayngrwtiip |
---|---|
hierarchy_sort_str |
2013 |
publishDate |
2013 |
allfields |
10.1515/jpem-2013-0064 doi artikel_Grundlieferung.pp (DE-627)NLEJ247123161 DE-627 ger DE-627 rakwb Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report De Gruyter 2013 4 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. Walter de Gruyter Online Zeitschriften anti-GH antibodies growth hormone (GH) deficiency growth hormone (GH) therapy Meazza, Cristina oth Schaab, Michael oth Pagani, Sara oth Calcaterra, Valeria oth Bozzola, Elena oth Kratzsch, Juergen oth Bozzola, Mauro oth Enthalten in The journal of pediatric endocrinology and metabolism Berlin [u.a.] : de Gruyter, 1985 26(2013), 7-8 vom: 02. Apr., Seite 785-788 (DE-627)NLEJ248236202 (DE-600)2583847-7 2191-0251 nnns volume:26 year:2013 number:7-8 day:02 month:04 pages:785-788 extent:4 https://doi.org/10.1515/jpem-2013-0064 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 26 2013 7-8 02 04 785-788 4 |
spelling |
10.1515/jpem-2013-0064 doi artikel_Grundlieferung.pp (DE-627)NLEJ247123161 DE-627 ger DE-627 rakwb Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report De Gruyter 2013 4 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. Walter de Gruyter Online Zeitschriften anti-GH antibodies growth hormone (GH) deficiency growth hormone (GH) therapy Meazza, Cristina oth Schaab, Michael oth Pagani, Sara oth Calcaterra, Valeria oth Bozzola, Elena oth Kratzsch, Juergen oth Bozzola, Mauro oth Enthalten in The journal of pediatric endocrinology and metabolism Berlin [u.a.] : de Gruyter, 1985 26(2013), 7-8 vom: 02. Apr., Seite 785-788 (DE-627)NLEJ248236202 (DE-600)2583847-7 2191-0251 nnns volume:26 year:2013 number:7-8 day:02 month:04 pages:785-788 extent:4 https://doi.org/10.1515/jpem-2013-0064 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 26 2013 7-8 02 04 785-788 4 |
allfields_unstemmed |
10.1515/jpem-2013-0064 doi artikel_Grundlieferung.pp (DE-627)NLEJ247123161 DE-627 ger DE-627 rakwb Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report De Gruyter 2013 4 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. Walter de Gruyter Online Zeitschriften anti-GH antibodies growth hormone (GH) deficiency growth hormone (GH) therapy Meazza, Cristina oth Schaab, Michael oth Pagani, Sara oth Calcaterra, Valeria oth Bozzola, Elena oth Kratzsch, Juergen oth Bozzola, Mauro oth Enthalten in The journal of pediatric endocrinology and metabolism Berlin [u.a.] : de Gruyter, 1985 26(2013), 7-8 vom: 02. Apr., Seite 785-788 (DE-627)NLEJ248236202 (DE-600)2583847-7 2191-0251 nnns volume:26 year:2013 number:7-8 day:02 month:04 pages:785-788 extent:4 https://doi.org/10.1515/jpem-2013-0064 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 26 2013 7-8 02 04 785-788 4 |
allfieldsGer |
10.1515/jpem-2013-0064 doi artikel_Grundlieferung.pp (DE-627)NLEJ247123161 DE-627 ger DE-627 rakwb Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report De Gruyter 2013 4 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. Walter de Gruyter Online Zeitschriften anti-GH antibodies growth hormone (GH) deficiency growth hormone (GH) therapy Meazza, Cristina oth Schaab, Michael oth Pagani, Sara oth Calcaterra, Valeria oth Bozzola, Elena oth Kratzsch, Juergen oth Bozzola, Mauro oth Enthalten in The journal of pediatric endocrinology and metabolism Berlin [u.a.] : de Gruyter, 1985 26(2013), 7-8 vom: 02. Apr., Seite 785-788 (DE-627)NLEJ248236202 (DE-600)2583847-7 2191-0251 nnns volume:26 year:2013 number:7-8 day:02 month:04 pages:785-788 extent:4 https://doi.org/10.1515/jpem-2013-0064 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 26 2013 7-8 02 04 785-788 4 |
allfieldsSound |
10.1515/jpem-2013-0064 doi artikel_Grundlieferung.pp (DE-627)NLEJ247123161 DE-627 ger DE-627 rakwb Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report De Gruyter 2013 4 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. Walter de Gruyter Online Zeitschriften anti-GH antibodies growth hormone (GH) deficiency growth hormone (GH) therapy Meazza, Cristina oth Schaab, Michael oth Pagani, Sara oth Calcaterra, Valeria oth Bozzola, Elena oth Kratzsch, Juergen oth Bozzola, Mauro oth Enthalten in The journal of pediatric endocrinology and metabolism Berlin [u.a.] : de Gruyter, 1985 26(2013), 7-8 vom: 02. Apr., Seite 785-788 (DE-627)NLEJ248236202 (DE-600)2583847-7 2191-0251 nnns volume:26 year:2013 number:7-8 day:02 month:04 pages:785-788 extent:4 https://doi.org/10.1515/jpem-2013-0064 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 26 2013 7-8 02 04 785-788 4 |
source |
Enthalten in The journal of pediatric endocrinology and metabolism 26(2013), 7-8 vom: 02. Apr., Seite 785-788 volume:26 year:2013 number:7-8 day:02 month:04 pages:785-788 extent:4 |
sourceStr |
Enthalten in The journal of pediatric endocrinology and metabolism 26(2013), 7-8 vom: 02. Apr., Seite 785-788 volume:26 year:2013 number:7-8 day:02 month:04 pages:785-788 extent:4 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
anti-GH antibodies growth hormone (GH) deficiency growth hormone (GH) therapy |
isfreeaccess_bool |
false |
container_title |
The journal of pediatric endocrinology and metabolism |
authorswithroles_txt_mv |
Meazza, Cristina @@oth@@ Schaab, Michael @@oth@@ Pagani, Sara @@oth@@ Calcaterra, Valeria @@oth@@ Bozzola, Elena @@oth@@ Kratzsch, Juergen @@oth@@ Bozzola, Mauro @@oth@@ |
publishDateDaySort_date |
2013-04-02T00:00:00Z |
hierarchy_top_id |
NLEJ248236202 |
id |
NLEJ247123161 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ247123161</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20220820030443.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2013 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/jpem-2013-0064</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ247123161</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">De Gruyter</subfield><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-GH antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">growth hormone (GH) deficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">growth hormone (GH) therapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meazza, Cristina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schaab, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pagani, Sara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calcaterra, Valeria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bozzola, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kratzsch, Juergen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bozzola, Mauro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The journal of pediatric endocrinology and metabolism</subfield><subfield code="d">Berlin [u.a.] : de Gruyter, 1985</subfield><subfield code="g">26(2013), 7-8 vom: 02. Apr., Seite 785-788</subfield><subfield code="w">(DE-627)NLEJ248236202</subfield><subfield code="w">(DE-600)2583847-7</subfield><subfield code="x">2191-0251</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:7-8</subfield><subfield code="g">day:02</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:785-788</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/jpem-2013-0064</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2013</subfield><subfield code="e">7-8</subfield><subfield code="b">02</subfield><subfield code="c">04</subfield><subfield code="h">785-788</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
series2 |
Walter de Gruyter Online Zeitschriften |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ248236202 |
format |
electronic Article |
delete_txt_mv |
keep |
collection |
NL |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
2191-0251 |
topic_title |
Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report anti-GH antibodies growth hormone (GH) deficiency growth hormone (GH) therapy |
publisher |
De Gruyter |
publisherStr |
De Gruyter |
topic |
misc anti-GH antibodies misc growth hormone (GH) deficiency misc growth hormone (GH) therapy |
spellingShingle |
misc anti-GH antibodies misc growth hormone (GH) deficiency misc growth hormone (GH) therapy Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report |
topic_unstemmed |
misc anti-GH antibodies misc growth hormone (GH) deficiency misc growth hormone (GH) therapy |
topic_browse |
misc anti-GH antibodies misc growth hormone (GH) deficiency misc growth hormone (GH) therapy |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
author2_variant |
c m cm m s ms s p sp v c vc e b eb j k jk m b mb |
hierarchy_parent_title |
The journal of pediatric endocrinology and metabolism |
hierarchy_parent_id |
NLEJ248236202 |
hierarchy_top_title |
The journal of pediatric endocrinology and metabolism |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)NLEJ248236202 (DE-600)2583847-7 |
title |
Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report |
ctrlnum |
(DE-627)NLEJ247123161 |
title_full |
Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report |
journal |
The journal of pediatric endocrinology and metabolism |
journalStr |
The journal of pediatric endocrinology and metabolism |
isOA_bool |
false |
recordtype |
marc |
publishDateSort |
2013 |
contenttype_str_mv |
txt |
container_start_page |
785 |
container_volume |
26 |
physical |
4 |
format_se |
Elektronische Aufsätze |
doi_str_mv |
10.1515/jpem-2013-0064 |
title_sort |
development of antibodies against growth hormone (gh) during rhgh therapy in a girl with idiopathic gh deficiency: a case report |
title_auth |
Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report |
abstract |
A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. |
abstractGer |
A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. |
abstract_unstemmed |
A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy. |
collection_details |
GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE |
container_issue |
7-8 |
title_short |
Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report |
url |
https://doi.org/10.1515/jpem-2013-0064 |
remote_bool |
true |
author2 |
Meazza, Cristina Schaab, Michael Pagani, Sara Calcaterra, Valeria Bozzola, Elena Kratzsch, Juergen Bozzola, Mauro |
author2Str |
Meazza, Cristina Schaab, Michael Pagani, Sara Calcaterra, Valeria Bozzola, Elena Kratzsch, Juergen Bozzola, Mauro |
ppnlink |
NLEJ248236202 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth |
doi_str |
10.1515/jpem-2013-0064 |
up_date |
2024-07-06T10:00:20.514Z |
_version_ |
1803823371270488064 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ247123161</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20220820030443.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2013 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/jpem-2013-0064</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ247123161</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of antibodies against growth hormone (GH) during rhGH therapy in a girl with idiopathic GH deficiency: a case report</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">De Gruyter</subfield><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A 12.5-year-old Italian girl was referred to our institute for progressive growth failure from the age of 6 years, with a height of 128.2 cm (–3.37 SDS) and a bone age of 9 years. Endocrinological evaluation revealed a partial growth hormone deficiency (GHD) and GH therapy was started at a dosage of 0.25 mg/kg/week. During the first 3 years, she showed an increase in growth rate and experienced pubertal development onset. Then a poor growth rate (2 cm/year=0.43 SDS) was observed, notwithstanding an increase in GH dosage (0.35 mg/kg/week) and good compliance. We found a positive anti-GH antibody titre (1:1850, cutoff 1/100), confirmed 6 months later (1:2035); the antibodies had low binding capacity (0.63 μg/mL) and were only partially capable of inhibiting the GH effect. However, GH treatment was discontinued, and after 3 months the antibody titre decreased (1:950). In conclusion, we suggest evaluation of anti-GH antibodies in GH-treated idiopathic GHD children in whom growth response decreases after some years of therapy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-GH antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">growth hormone (GH) deficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">growth hormone (GH) therapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meazza, Cristina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schaab, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pagani, Sara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calcaterra, Valeria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bozzola, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kratzsch, Juergen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bozzola, Mauro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The journal of pediatric endocrinology and metabolism</subfield><subfield code="d">Berlin [u.a.] : de Gruyter, 1985</subfield><subfield code="g">26(2013), 7-8 vom: 02. Apr., Seite 785-788</subfield><subfield code="w">(DE-627)NLEJ248236202</subfield><subfield code="w">(DE-600)2583847-7</subfield><subfield code="x">2191-0251</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:7-8</subfield><subfield code="g">day:02</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:785-788</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/jpem-2013-0064</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2013</subfield><subfield code="e">7-8</subfield><subfield code="b">02</subfield><subfield code="c">04</subfield><subfield code="h">785-788</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
score |
7.4003057 |